1-866-735-2792
Talk to a personal injury lawyer.
Featured Topics Related Practices
Recall Announcements
- Zimmer Knee Implants: Certain Zimmer NexGen knee implant models are failing at a high rate...
- Ladder Recalls: Louisville Ladder recalled about 25,000 extension ladders carrying the “Michigan” and “Louisville/Davidson” brands...
- AED Heart Device Deaths: The FDA has notified consumers, hospitals, and medical professionals that Cardiac Science Corporation must recall Automated External Defibrillators...
- Defective Stroller Recall: Maclaren USA is recalling approximately one million strollers...
- Fosamax Lawsuits: Fosamax linked to serious side effect risks including osteonecrosis of the jaw, heart arrhythmia, thigh bone fractures, painful eye inflammations, and esophagus cancer.
Unsafe Drugs
$3.75 Billion Dollar Settlement in National Diet Drug Settlement Case. Sol Weiss started a nine week long trial in Middlesex County, New Jersey seeking medical monitoring screening benefits for New Jersey residents. The case was eventually stayed when Sol and other attorneys negotiated a $3.75 billion dollar settlement in the United States District Court for the Eastern District of Pennsylvania. David Jacoby assisted in the New Jersey State Court Trial.
$114.5 Million Settlement for Baycol Pharmaceutical Cases. Sol Weiss earned a $68.5 million dollar settlement for 168 people seriously injured by the statin drug Baycol. Sol negotiated the settlement with Bayer, which withdrew the medication from the market in 2001. Barry Hill negotiated another $46 million in Baycol settlements with Bayer for a separate group of clients.
900 Individual Diet Drug Victims Settle Lawsuits. Sol Weiss, along with David Jacoby, negotiated a confidential settlement for 900 individual diet drug lawsuits on behalf of clients from seven law firms in Pennsylvania and New Jersey.
Wyeth v. Levine: A Monumental Victory for Consumers. In a 6-3 decision March 4, the U.S. Supremem Court ruled in Wyeth v. Levin that, in the absence of express congressional intent, drug manufacturers could not use the federal preemption defense to escape liability for harm caused by thier products.
